Distinct representation of muscle weakness in QMG and MG-ADL - Authors' reply

Generalized myasthenia gravis: Clinical trials to watch.

Med (New York, N.Y.)·2026

Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+).

Frontiers in neurology·2026

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

JAMA neurology·2026

Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.

JAMA neurology·2026

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Neurology. Clinical practice·2026

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).

Journal of neurology·2026

Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies.

The Lancet. Neurology·2026

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.

The Lancet. Neurology·2026

Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy.

The Lancet. Neurology·2026

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.

The Lancet. Neurology·2026

Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Neurology·2026

Prevalence of unruptured intracranial aneurysms according to comorbidities, risk factors, country, and time period: a systematic review and meta-analysis.

The Lancet. Neurology·2026

Mechanism and Optimization of Quasi-Static Compression Performance in Hexagonal Honeycomb Sandwich Structures.

ACS omega·2026

Fibronectin's tensional state as a mechanical signature of fibrotic extracellular matrix in idiopathic pulmonary fibrosis models.

Matrix biology plus·2026

General Theoretical Framework Linking Macroscopic Stress to Microscopic Strand Conformations in Unentangled Elastomers.

Physical review letters·2026

Identification of Sodium/Myo-Inositol Transporter 1 as a Major Determinant of Arterial Contractility.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026

Fibrotic Substrate Stiffness Enhances Endometriotic Epithelial Cell Motility.

Tissue engineering. Part A·2026

Rib Plating of Recurrent, Nonunion Rib Stress Fractures in an Elite Athlete.

Annals of thoracic surgery short reports·2026

Related Experiment Videos

Distinct representation of muscle weakness in QMG and MG-ADL - Authors' reply

Related Concept Videos

Generalized myasthenia gravis: Clinical trials to watch.

Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+).

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).

Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies.

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.

Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy.

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.

Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Prevalence of unruptured intracranial aneurysms according to comorbidities, risk factors, country, and time period: a systematic review and meta-analysis.

Mechanism and Optimization of Quasi-Static Compression Performance in Hexagonal Honeycomb Sandwich Structures.

Fibronectin's tensional state as a mechanical signature of fibrotic extracellular matrix in idiopathic pulmonary fibrosis models.

General Theoretical Framework Linking Macroscopic Stress to Microscopic Strand Conformations in Unentangled Elastomers.

Identification of Sodium/Myo-Inositol Transporter 1 as a Major Determinant of Arterial Contractility.

Fibrotic Substrate Stiffness Enhances Endometriotic Epithelial Cell Motility.

Rib Plating of Recurrent, Nonunion Rib Stress Fractures in an Elite Athlete.

Related Experiment Videos

Distinct representation of muscle weakness in QMG and MG-ADL - Authors' reply

Related Concept Videos

Related Articles